FHTX · Foghorn Therapeutics Inc.
$7.07
+0.06 (+0.86%)
At close · Aug 21
Market Cap
$424.31M
Shares
59.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.07
Open$7.10
Day$6.95–7.35
52W close$3.53–7.07
Avg vol 30d281K
Short int1.6M · 2.7% float · 7.7d
Short vol38%
Last earningsAug 10, 2021
DataOct 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+41%
above
Price vs 50-day avg
+34%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+46%
trailing
6-month return
+23%
trailing
YTD return
+31%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.70% of float · ▲ +4.4% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-86.1M
Balance sheet
$80.9M
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jan 12, 2026
Cash, cash equivalents, and marketable securities
· As of January 13, 2026
$208.9M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+41%
Bullish
Price vs 50-day avg
+34%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Golden cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.70% of float · ▲ +4.4% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $7 · 100%
Range high $7
vs 200-day avg +41%
vs 50-day avg +34%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FHTX
this stock
Foghorn Therapeutics Inc.
|
$424.31M | +30.9% | +36.8% | — | 2.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FHTX | +12.9% | +45.8% | +22.7% | +56.1% | +30.9% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +14.3% | +42.1% | +11.2% | +53.6% | +18.6% |
Key facts
CIK
1822462
CUSIP
344174107
13F (30d)
95 filings
95 filers
Visit website
Investor relations